Making a meaningful difference in the lives of patients
Ascendis Pharma is building an integrated biopharmaceutical company to advance its pipeline of long-acting prodrug therapies. We employ our proprietary TransCon technology platform to generate therapeutics with best-in-class profiles that address large markets with significant unmet medical needs. We have a diversified and balanced high-value product pipeline, including internal programs and partnerships with market leaders.
Late-stage TransCon Growth Hormone
Our once-weekly TransCon Growth Hormone product candidate has a safety and efficacy profile that is comparable to daily growth hormone. TransCon Growth Hormone is the only late-stage long-acting growth hormone that has been shown to release unmodified growth hormone into the bloodstream at the same peak and total exposure levels as daily growth hormone injections. It is expected to enter a Phase 3 trial in mid-2016. Read More
Proprietary Technology Platform
Our TransCon technology creates novel, long-acting prodrugs of proteins, peptides and small molecules, suitable for either local or systemic treatment. By solving the fundamental limitations of previous approaches applied to extend duration of a drug’s action in the body, Ascendis Pharma believes its TransCon technology can enhance the benefit of a given therapeutic. Read More